%0 Journal Article %1 Oberthuer2007 %A Oberthuer, André %A Warnat, Patrick %A Kahlert, Yvonne %A Westermann, Frank %A Spitz, Rüdiger %A Brors, Benedikt %A Hero, Barbara %A Eils, Roland %A Schwab, Manfred %A Berthold, Frank %A Fischer, Matthias %D 2007 %J Cancer Lett %K Analysis Biological Expression Gene Genes, Humans; Markers, Neuroblastoma, Profiling; Tumor Variance; classification/genetics; myc; of %N 2 %P 250--267 %R 10.1016/j.canlet.2006.10.016 %T Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. %U http://dx.doi.org/10.1016/j.canlet.2006.10.016 %V 250 %X Currently, Pubmed lists 385 marker genes for neuroblastoma outcome. Using a customized neuroblastoma-microarray, we evaluated the prognostic impact of the gene-expression pattern of 349 of these candidates (90.6\%) in 127 neuroblastoma patients with divergent outcome. By significance analysis of microarrays (SAM) and both uncorrected and Bonferroni-corrected ANOVA, 166/349 (47.5\%), 218/349 (62.5\%) and 128/349 (36.4\%) candidates showed significant differential expression between patients with contrasting outcome. By Prediction Analysis for Microarrays (PAM), a 38-gene-classifier was derived from all markers, which classified patients outcome with an overall accuracy of 78.5\%. However, patients with unfavorable outcome of MYCN non-amplified disease were largely misclassified (accuracy: 35\%), suggesting that these courses are not identified by current marker genes.

@article{Oberthuer2007, __markedentry = {[bbrors:6]}, abstract = {Currently, Pubmed lists 385 marker genes for neuroblastoma outcome. Using a customized neuroblastoma-microarray, we evaluated the prognostic impact of the gene-expression pattern of 349 of these candidates (90.6\%) in 127 neuroblastoma patients with divergent outcome. By significance analysis of microarrays (SAM) and both uncorrected and Bonferroni-corrected ANOVA, 166/349 (47.5\%), 218/349 (62.5\%) and 128/349 (36.4\%) candidates showed significant differential expression between patients with contrasting outcome. By Prediction Analysis for Microarrays (PAM), a 38-gene-classifier was derived from all markers, which classified patients outcome with an overall accuracy of 78.5\%. However, patients with unfavorable outcome of MYCN non-amplified disease were largely misclassified (accuracy: 35\%), suggesting that these courses are not identified by current marker genes.}, added-at = {2015-04-09T12:36:21.000+0200}, author = {Oberthuer, Andr{\'{e}} and Warnat, Patrick and Kahlert, Yvonne and Westermann, Frank and Spitz, R{\"{u}}diger and Brors, Benedikt and Hero, Barbara and Eils, Roland and Schwab, Manfred and Berthold, Frank and Fischer, Matthias}, biburl = {https://www.bibsonomy.org/bibtex/2f0337d7519d133af32a619d4f6d80dcf/bbrors}, doi = {10.1016/j.canlet.2006.10.016}, institution = {Children's Hospital, Department of Pediatric Oncology and Hematology and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Kerpener Strasse 62, D-50924 Cologne, Germany. andre.oberthuer@uk-koeln.de}, interhash = {27c7707853be08f86a11bd6eb5b15ae8}, intrahash = {f0337d7519d133af32a619d4f6d80dcf}, journal = {Cancer Lett}, keywords = {Analysis Biological Expression Gene Genes, Humans; Markers, Neuroblastoma, Profiling; Tumor Variance; classification/genetics; myc; of}, language = {eng}, medline-pst = {ppublish}, month = Jun, number = 2, owner = {bbrors}, pages = {250--267}, pii = {S0304-3835(06)00571-4}, pmid = {17126996}, timestamp = {2015-04-09T12:36:21.000+0200}, title = {Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease.}, url = {http://dx.doi.org/10.1016/j.canlet.2006.10.016}, volume = 250, year = 2007 }